Related Research Articles
Emil "Tom" Frei III was an American physician and oncologist. He was the former director and former physician-in-chief of the Dana–Farber Cancer Institute in Boston, Massachusetts. He was also the Richard and Susan Smith Distinguished Professor of Medicine at Harvard Medical School.
Graham Andrew Colditz MD, DrPH is an Australian chronic disease epidemiologist. He is the inaugural Niess-Gain Professor at Washington University School of Medicine, where he is associate director for Prevention and Control at the Alvin J. Siteman Cancer Center. He directs the Master of Population Health Science at Washington University School of Medicine. During medical training he was excited by the potential for prevention of chronic diseases. With encouragement from mentors he pursued training in the US as it was routine for academics in Australia to obtain overseas training at that time. He is internationally recognized for leadership in cancer prevention, and is often interviewed by media for input on this topic. With members of Cancer Prevention and Control at Siteman, he blogs on issues relating to cancer prevention and screening. According to Google Scholar statistics, Colditz has a h-index of more than 300. Colditz was a member of the Institute of Medicine Committee to Review Adverse Effects of Vaccines but resigned, along with Ruby H. N. Nguyen, before it produced its seminal report.
Edison T. Liu is an American chemist who is the former president and CEO of The Jackson Laboratory, and the former director of its NCI-designated Cancer Center (2012-2021). Before joining The Jackson Laboratory, he was the founding executive director of the Genome Institute of Singapore (GIS), chairman of the board of the Health Sciences Authority, and president of the Human Genome Organization (HUGO) (2007-2013). As the executive director of the GIS, he brought the institution to international prominence as one of the most productive genomics institutions in the world.
Charles L. Sawyers is a Howard Hughes Medical Institute (HHMI) investigator who holds the Marie-Josée and Henry R. Kravis Chair of the Human Oncology and Pathogenesis Program (HOPP) at Memorial Sloan Kettering Cancer Center (MSK). HOPP is a program created in 2006 that comprises researchers from many disciplines to bridge clinical and laboratory discoveries.
Eric D. Green is an American genomics researcher who had significant involvement in the Human Genome Project. He is the director of the National Human Genome Research Institute (NHGRI) at the National Institutes of Health (NIH), a position he has held since 2009.
Aviv Regev is a computational biologist and systems biologist and Executive Vice President and Head of Genentech Research and Early Development in Genentech/Roche. She is a core member at the Broad Institute of MIT and Harvard and professor at the Department of Biology of the Massachusetts Institute of Technology. Regev is a pioneer of single cell genomics and of computational and systems biology of gene regulatory circuits. She founded and leads the Human Cell Atlas project, together with Sarah Teichmann.
Michael A. Caligiuri is an American physician scientist focused on oncology and immunology. He is currently the president of the City of Hope National Medical Center and the Deana and Steve Campbell Physician-in-Chief Distinguished Chair. He was elected president of the American Association for Cancer Research, the world's largest cancer research organization, for 2017–2018. He was previously the CEO of the James Cancer Hospital (2008-2017), Director of the Comprehensive Cancer Center (2003-2017), and Director of the Division of Hematology-Oncology (2000-2008) at the Ohio State University. He was elected to the United States National Academy of Medicine in 2018.
Webster K. "Web" Cavenee is the Director of Strategic Alliances in Central Nervous System Cancers at the Ludwig Institute for Cancer Research and Distinguished Professor at the University of California, San Diego. He was the Director of the Ludwig Institute for Cancer Research until 2015 when it was taken over by Richard Kolodner. His laboratory studies gene mutations in cancer, most notably in EGFR and glioblastoma multiforme.
Charles J. Sherr is the chair of the Tumor Cell Biology Department at St. Jude Children's Research Hospital. He studies tumor suppressor genes and cell division.
Professor Carol L. Prives FRS is the Da Costa Professor of Biological Sciences at Columbia University. She is known for her work in the characterisation of p53, an important tumor suppressor protein frequently mutated in cancer.
Donald Straley Coffey was the Catherine Lola and J. Smith Michael distinguished professor of Urology at the Johns Hopkins University School of Medicine and subsequently professor emeritus. He had a primary appointment to urology and secondary appointments to oncology, pharmacology and pathology.
Daniel D. Von Hoff is the physician in chief and director of translational research at Translational Genomics Research Institute (TGen), and current Virginia G. Piper Distinguished Chair for Innovative Cancer Research at HonorHealth Clinical Research Institute. He is also a professor of medicine at the Mayo Clinic and medical director of research as well as chief scientific officer at US Oncology. He is most notable for his work in targeted therapies for the treatment of cancer. He led the development of gemcitabine, and has several drugs in development.
Bruce Allan Chabner is an American medical oncologist and researcher who worked at the National Cancer Institute and now is a professor of medicine at Harvard Medical School. He is also the director of clinical research at the Cancer Center at Massachusetts General Hospital. His expansive research of cancer pharmacology most notably includes his contributions to developing anti-folate drugs for the treatment of cancer. His work at NIH led to the development of Taxol, a commonly prescribed breast cancer drug.
Kenneth Wayne Kinzler is a professor of oncology, and director of the Ludwig Center at Johns Hopkins University at the Sidney Kimmel Comprehensive Cancer Center.
Kornelia Polyak is a professor of medicine at Harvard Medical School and an internationally recognized breast cancer expert.
Richard D. Klausner is an American scientist who served as the 11th director of the National Cancer Institute of the United States.
Christina Messineo Annunziata is an American medical oncologist researching molecular signal transduction in ovarian cancer. She is an investigator in the National Cancer Institute's women's malignancies branch and head of the translational genomics section.
Dr. Michael J. Lenardo, is the chief of the Molecular Development and Immune System Section and the founder and co-Director of the Clinical Genomics Program at the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH). Trained as a geneticist, molecular biologist, and immunologist, his research examines how cells of the immune system defend themselves against various pathogens, including viruses and bacteria. His research has investigated genetic abnormalities in the immune system, mechanisms of cell death, genetic diseases of immune homeostasis and autoimmunity, and development of novel diagnostics and therapeutics for diseases of the immune system. Lenardo's contributions to science and medicine have shown the possibilities of genomic research in developing precision medicine diagnoses and treatments for disease in humans. In 2006 he was appointed Officer of the Most Excellent Order of the British Empire (O.B.E.) by Queen Elizabeth II. In 2019 he was inducted into the National Academies of Sciences and the National Academy of Medicine, considered among the highest honors awarded to a U.S scientist and medical researcher respectively.
Adekunle O. Odunsi is an American gynecologic oncologist. In 2021, Odunsi became the director of the University of Chicago Comprehensive Cancer Center.
Philip Greenberg is a professor of medicine, oncology, and immunology at the University of Washington and head of program in immunology at the Fred Hutchinson Cancer Research Center. His research is centered around T cell biology and therapeutic cell therapies. He is a co-founder of Juno Therapeutics.
References
- ↑ "Louis Staudt". www.nasonline.org.
- 1 2 "Louis M. Staudt, MD, PhD | NCI Genomic Data Commons". gdc.cancer.gov.
- ↑ "AACR Princess Takamatsu Memorial Lectureship". www.aacr.org.[ permanent dead link ]
- 1 2 https://www.biochem2.com/pdf/perspectives_Lectures/Oncology/Staudt/Staudt_CV.pdf.
{{cite web}}: Missing or empty|title=(help)
| International | |
|---|---|
| National | |
